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Genetic dissection of mammalian ERAD through
comparative haploid and CRISPR forward genetic
screens
Richard T. Timms1,*, Sam A. Menzies1,*, Iva A. Tchasovnikarova1,*, Lea C. Christensen2,*, James C. Williamson1,
Robin Antrobus1, Gordon Dougan3, Lars Ellgaard2 & Paul J. Lehner1
The application of forward genetic screens to cultured human cells represents a powerful
method to study gene function. The repurposing of the bacterial CRISPR/Cas9 system
provides an effective method to disrupt gene function in mammalian cells, and has
been applied to genome-wide screens. Here, we compare the efﬁcacy of genome-wide
CRISPR/Cas9-mediated forward genetic screens versus gene-trap mutagenesis screens in
haploid human cells, which represent the existing ‘gold standard’ method. This head-to-head
comparison aimed to identify genes required for the endoplasmic reticulum-associated
degradation (ERAD) of MHC class I molecules. The two approaches show high concordance
(470%), successfully identifying the majority of the known components of the canonical
glycoprotein ERAD pathway. Both screens also identify a role for the uncharacterized
gene TXNDC11, which we show encodes an EDEM2/3-associated disulphide reductase.
Genome-wide CRISPR/Cas9-mediated screens together with haploid genetic screens provide
a powerful addition to the forward genetic toolbox.
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A
lthough our understanding of the gene has advanced
considerably since the pioneering work of Muller in the
1920s (ref. 1), the basic principle of the forward genetic
screen has remained the same: a population of cells are
mutagenized to create a library of gene knockouts, which can
then be screened for mutants defective in the pathway of interest
and the responsible genes identiﬁed by mapping the causative
mutations. This approach has proved enormously successful in
identifying gene function in a range of model eukaryotic organisms,
but the difﬁculty in generating bi-allelic mutations in diploid cells
has limited the application of this approach in human cells.
Until recently the only practical way of carrying out
genome-wide loss-of-function screens in cultured human cells was
via RNA interference, whereby short double-stranded RNAs loaded
onto the RNA-induced silencing complex target the endonucleolytic
cleavage of cognate messenger RNA (mRNA) targets2. This method
circumvents the problem of diploidy as it acts at the mRNA level,
and can therefore be carried out in the cell type of choice. Although
genome-wide screens performed via transfection of short interfering
RNAs (siRNAs) are expensive and labour-intensive, pooled screens
can be performed using lentiviral expression libraries of short
hairpin RNA (shRNA) constructs3,4. However, RNA interference-
based screening approaches are limited by: (1) incomplete
knockdown of gene expression, (2) the variable degree of
suppression observed with different siRNAs and (3) off-target
effects, whereby a non-cognate mRNA is silenced to a similar extent
as the intended target5.
An important breakthrough in the ﬁeld of experimental human
genetics was the demonstration that the near-haploid human
KBM7 cell line could be used to perform forward genetic
screens6. Gene inactivation on a haploid background results in a
loss-of-gene function, and so insertional mutagenesis of KBM7
cells with a gene-trap retroviral vector can be used to create a
library of gene knockouts7. Haploid genetic screens in KBM7 cells
and their partially reprogrammed derivative HAP1 have
successfully assigned functions to a suite of genes involved in a
wide variety of cellular processes8–11, and the derivation of
haploid embryonic stem cells12,13 now permits a similar approach
in cultured murine cells14,15. As such, haploid genetic screens
currently represent the ‘best-in-class’ method for the forward
genetic analysis of cultured human cells.
Custom genome editing using programmable nucleases is a
transformative technology for cell biologists. The deployment of
the bacterial CRISPR/Cas9 system in human cells now offers—for
the ﬁrst time—a practical method to generate bi-allelic mutation
and hence functional gene knockouts16. Through the synthesis of
a large library of guide RNAs (sgRNAs) to target the Cas9
nuclease to all known genes, CRISPR-mediated gene disruption
can be applied on a genome-scale to perform forward genetic
screens17–19. The major attraction of this approach is that, unlike
haploid screens, CRISPR screens can theoretically be performed
in any cell type, including primary cells20 or even in vivo21.
However, there are some potential technical caveats that may
limit the effectiveness of CRISPR screens, such as the variable
efﬁcacy of gene disruption by different sgRNAs, the potential for
off-target effects, and the requirement for maintaining even
representation across a large expression library containing
thousands of individual sgRNAs.
Here, we set out to directly compare the effectiveness of the
two approaches in a head-to-head comparison. We chose to study
the process of endoplasmic reticulum-associated degradation
(ERAD), in which misfolded proteins of the early secretory
pathway are recruited to the cellular dislocation machinery and
retrotranslocated back across the ER membrane to the cytosol for
proteasomal degradation22. Previously, we showed that the major
histocompatibility complex class I (MHC-I) heavy chain HLA-A2
is a substrate for ERAD through the canonical glycoprotein
quality control pathway23,24. This pathway is initiated by the
sequential trimming of mannose residues from the N-linked
glycans of misfolded polypeptides by the EDEM proteins25,
which mediates their targeting to the Hrd1–SEL1L complex26.
These misfolded substrates are subsequently retrotranslocated
from the ER, ubiquitinated, released into the cytosol and ﬁnally
degraded by the proteasome.
Our results indicate that both haploid gene-trap and
CRISPR/Cas9-mediated screening techniques represent highly
effective tools to identify the genes involved in cellular processes.
Moreover, both approaches highlight an essential role for
the uncharacterized gene TXNDC11 in glycoprotein ERAD,
which we show encodes an EDEM2/3-associated disulphide
reductase.
Results
A ﬂuorescent reporter system to monitor MHC-I ERAD. To
perform parallel haploid and CRISPR forward genetic screens to
identify the genes involved in MHC-I ERAD (Fig. 1a), we ﬁrst
needed to establish an ERAD reporter system in near-haploid
KBM7 cells11,27. We transduced KBM7 cells with a lentiviral
vector encoding a green ﬂuorescent protein (GFP)-tagged
HLA-A2 and isolated single cell clones. For the screens
we selected a clone that exhibited a low level of
GFP ﬂuorescence at steady-state and which showed a robust
increase in GFP ﬂuorescence upon depletion of SEL1L (Fig. 1b),
a key component of the MHC-I ERAD pathway23, indicating
that the GFP-HLA-A2 fusion protein was indeed degraded
via ERAD.
A haploid gene-trap screen for MHC-I ERAD. Following
retroviral gene-trap mutagenesis we sequentially enriched for
GFPhigh cells by two rounds of ﬂuorescence-activated cell sorting
(FACS), and isolated a relatively pure population of GFPhigh cells
(Fig. 1c). To identify the inactivated genes responsible for the
impaired degradation of GFP-HLA-A2, we mapped the retroviral
integration sites in the selected cells by linear ampliﬁcation-
mediated PCR (LAM-PCR) and Illumina sequencing7. This
revealed a suite of genes that were signiﬁcantly enriched in the
selected cells as compared with an unselected control population
(Fig. 1d and Supplementary Data 1). These genes could be readily
grouped into three functional classes. The largest group
comprised genes known to be involved in ERAD, including the
mannosidases EDEM1 and EDEM2, the E3 ubiquitin ligase
Hrd1 (encoded by the SYVN1 gene) and its binding partners
SEL1L and Derlin-2, and the E2 ubiquitin conjugases UBE2J1 and
UBE2G2 (Fig. 1e). We have previously shown a functional
requirement for the majority of these genes in the MHC-I ERAD
pathway23,24. The second group included a large number of
genes involved in N-glycosylation, including all three members
of the dolichol–phosphate–mannose (DPM) synthase complex
required for the generation of mannosyl donors28, and two
mannosyltransferase enzymes, ALG3 and ALG9 (Fig. 1e). As the
glycoprotein ERAD machinery recognizes substrates through
trimming of mannose residues on N-glycans25, it follows that
deletion of any of these genes might prevent recognition of GFP-
HLA-A2 as an ERAD substrate. Unexpectedly we also identiﬁed
three genes known to be involved in nonsense-mediated decay,
suggesting that the GFP reporter was also subject to degradation
at the RNA level. We selected a subset of the genes for
further validation, and found that CRISPR/Cas9-mediated gene
disruption did indeed result in impaired degradation of the
GFP-HLA-A2 substrate (Fig. 1f).
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A parallel CRISPR screen for MHC-I ERAD. Forward genetic
screens using genome-wide CRISPR/Cas9-mediated gene
disruption have recently emerged as an alternative method to
gene-trap haploid screens to examine gene function in cultured
mammalian cells17–19,29. To directly compare the efﬁcacy of the
two techniques, we performed a parallel CRISPR screen in the
same KBM7 clone carrying the GFP-HLA-A2 reporter (Fig. 2a).
We stably introduced the Cas9 nuclease via lentiviral transduction
and then carried out genome-wide CRISPR-mediated mutagenesis
using the GeCKO v2 library, which contains 123,411 sgRNAs
targeting 19,050 protein-coding genes30. Again, we enriched
for mutant GFPhigh cells by two round of FACS (Fig. 2b), and
then quantiﬁed sgRNA abundance in the selected cells versus the
unsorted mutant library by deep sequencing18. We observed
strong enrichment for individual sgRNAs targeting the ERAD
factors identiﬁed by the haploid screen (Fig. 2c). We then used the
RSA algorithm31 to identify the hits that were consistently
enriched by multiple sgRNAs targeting the same gene (Fig. 2d,e
and Supplementary Data 2). Strikingly, high concordance
was observed between the data from the CRISPR screen and
the haploid screen. Altogether, the two approaches identiﬁed
22 signiﬁcantly enriched genes: 16 of these genes (470%)
were identiﬁed in both screens, while 3 additional genes were
differentially highlighted by each technique (Fig. 2f).
In an attempt to further understand the reasons for this
differential identiﬁcation, we selected four of these genes for
further validation (Supplementary Fig. 1). We found that all
four represented true hits: in every case, individual CRISPR/Cas9-
mediated gene disruption experiments resulted in an increase in
GFP-HLA-A2 levels (Supplementary Fig. 1a). SMG6 and UPF2
therefore represent false-negatives on the CRISPR screen.
Examination of the unselected control library showed that all
six sgRNAs targeting these two genes were detected in this
sample, but that only one of the six sgRNAs in each case was
enriched in the selected population (Supplementary Fig. 1b). This
false-negative result is therefore likely to be due to these guides
being ineffective. Similarly, SMG7 and ALG12 represent false-
negatives on the haploid gene-trap screen. Gene-trap integrations
into SMG7 were not enriched in the selected cells (Supplementary
Fig. 1c). ALG12 falls just below our stringent cut-off for statistical
signiﬁcance, suggesting that this gene would have been identiﬁed
had more unique integrations sites been mapped, which could be
achieved through deeper sequencing coverage. A relatively small
number of integrations into ALG12 were detected, suggesting that
this gene may lie in a relative ‘cold-spot’ for retroviral integration
(Supplementary Fig. 1c). Indeed, one potential advantage of the
CRISPR approach is that it is not subject to the inherent bias of
insertional retroviral mutagenesis. In our comparison the sgRNA
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Figure 1 | A haploid genetic screen identiﬁes genes required for glycoprotein ERAD. (a) Schematic view of the haploid genetic screen to identify the
genes required for glycoprotein ERAD. (b) Isolation of a KBM7 clone in which the GFP-HLA-A2 reporter is undergoing ERAD, as evidenced by increased
GFP-HLA-A2 expression upon depletion of SEL1L. (c) Following gene-trap retroviral mutagenesis, rare GFPhigh cells were isolated via two rounds of FACS.
(d) Bubble plot illustrating the hits from the screen. Bubble size is proportional to the number of independent gene-trap integrations in each gene
predicted to inactivate gene expression (number in parentheses). (e) Schematic representation of the cellular pathways in which the screen hits function.
(f) CRISPR/Cas9-mediated validation of a subset of the screen hits.
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library provided more even mutagenic coverage across the
genome (Supplementary Fig. 1d,e), although the retroviral gene-
trap vector does preferentially target transcriptionally-active
genes7. Overall, these data suggest that the two methods are
both highly effective at identifying relevant genes, although
neither approach alone would appear to be saturating.
TXNDC11 is an ER-resident thioredoxin domain protein.
Forward genetic screens provide a powerful means to identify
functional roles for novel genes in cellular pathways. Both the
haploid and CRISPR screening methods identiﬁed TXNDC11, an
uncharacterized member of the protein disulphide isomerase (PDI)
family, as a novel protein putatively involved in ERAD. TXNDC11,
also known as EFP1, was originally identiﬁed as a binding partner
for the hydrogen peroxide-generating enzyme dual oxidase 1
(DUOX1) in a yeast two-hybrid screen32, but nothing is known
about its cellular function. TXNDC11 is annotated as encoding a
transmembrane protein with a short cytoplasmic amino-terminus,
a single transmembrane domain and a large luminal portion
(Fig. 3a). Homology modelling of the luminal portion predicted
ﬁve thioredoxin-like (Trx) domains at the core of the protein, plus
a coiled-coil region at the carboxy-terminus (Fig. 3b and
Supplementary Fig. 2). Such coiled-coil regions often mediate
protein oligomerization, and indeed we observed oligomerization
of recombinant TXNDC11 coiled-coil domain constructs with
different afﬁnity tags expressed in Escherichia coli (Supplementary
Fig. 3). However, the coiled-coil domain was not critical for
TXNDC11 function, as exogenous expression of a TXNDC11
mutant construct lacking this domain was still able to rescue the
degradation of GFP-HLA-A2 in TXNDC11 knockout cells
generated through CRISPR/Cas9-mediated gene disruption
(Supplementary Fig. 4). Immunoﬂuorescence analysis of epitope-
tagged TXNDC11 in HeLa cells suggested that the protein resides
predominantly in the ER (Fig. 3c), and this was supported
biochemically by sensitivity to digestion with Endoglycosidase H
(EndoH) (Fig. 3d). Both endogenous (Fig. 3d) and exogenous
(Fig. 3e) TXNDC11 migrated as a doublet on polyacrylamide
gels; the faster migrating band may represent a soluble
TXNDC11 isoform derived from partial signal peptidase cleavage
(Supplementary Fig. 5).
Redox activity of TXNDC11 is required for efﬁcient MHC-I
ERAD. PDI-family proteins catalyze the formation and reduction
of disulphide bonds in the ER through catalytic thioredoxin-like
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Figure 2 | A parallel CRISPR/Cas9-mediated forward genetic screen identiﬁes genes required for glycoprotein ERAD. (a,b) A CRISPR-mediated forward
genetic screen to identify the genes required for glycoprotein ERAD. Cas9 was stably expressed in the same GFP-HLA-A2 KBM7 clone, CRISPR-mediated
mutagenesis was performed using the GeCKO v2 sgRNA library, and rare GFPhigh cells isolated by two rounds of FACS. (c) Individual sgRNAs targeting ERAD
factors previously identiﬁed by the haploid genetic screen were highly enriched in the selected GFPhigh cells as compared with the unselected mutant library.
The dotted line represents the linear regression line of best ﬁt. (d) Bubble plot illustrating the hits from the CRISPR screen. The RSA algorithm was used to
identify the signiﬁcantly enriched genes targeted in the selected cells. Bubble size is proportional to the number of active sgRNAs per gene. (e) The number of
active sgRNAs for each of the screen hits, as identiﬁed by the RSA algorithm. (f) Overlap of the screen hits from the haploid and CRISPR forward genetic
screens.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11786
4 NATURE COMMUNICATIONS | 7:11786 | DOI: 10.1038/ncomms11786 | www.nature.com/naturecommunications
domains containing two cysteine residues in a CXXC active site
motif. Of the ﬁve predicted Trx domains in TXNDC11, only Trx5
contains a CXXC active site motif; Trx1 contains a CXXS motif,
while Trx2, Trx3 and Trx4 lack any active site cysteine residues
(Fig. 3b). To determine whether oxidoreductase activity of
TXNDC11 might be important for its function, we therefore
mutated the active site cysteine residues of Trx5 to alanine
(Fig. 3e). Unlike the wild-type TXNDC11 protein, the TXNDC11
Trx5 (AXXA) mutant was no longer able to rescue GFP-HLA-A2
degradation in cells lacking TXNDC11, supporting a redox
role for TXNDC11 (Fig. 3f). We therefore expressed the active
Trx5 domain in E. coli (Supplementary Fig. 6) and examined
the properties of the puriﬁed domain in vitro. The active site
disulphide of Trx5 was found to be very stable, with an estimated
reduction potential of B 234mV (Fig. 3g and Supplementary
Fig. 5d). This value is considerably more reducing than that of
other PDI-family members33–35, indicating a redox function for
TXNDC11 as a reductase.
The relevant target of this reductase activity could either be the
ERAD substrate itself or a component of the ERAD machinery.
We found that depletion of TXNDC11 (Fig. 3h) also impaired
the degradation of three additional ERAD substrates: the
unassembled CD3 delta chain (CD3d), the unassembled TCR
alpha chain (TCRa) and the Null-Hong Kong (NHK) variant of
alpha-1 antitrypsin (Fig. 3i). We further explored substrate
requirements by constructing two mutants of NHK: NHK(QQQ),
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Figure 3 | TXNDC11 is a disulphide reductase involved in glycoprotein ERAD. (a,b) Predicted architecture of the TXNDC11 protein. In (b), potential
N-glycosylation sites are indicated with asterisks. (c,d) Epitope-tagged TXNDC11 predominantly localizes to the ER as assessed by co-localization with
calnexin by immunoﬂuorescence (c), supported biochemically by sensitivity to digestion with EndoH (d). (c) Scale bar, 20mm. (e,f) Genetic reconstitution
of TXNDC11 knockout cells. Expression of wild-type TXNDC11 rescues GFP-HLA-A2 degradation in TXNDC11 knockout cells. Mutation of the active site
cysteine residues of the Trx5 domain, but not the Trx1 domain, abolishes the function of TXNDC11. (g) Redox titration of the TXNDC11 Trx5 domain with
lipoic acid (DHLA/LA). The redox state of the puriﬁed Trx5 domain was assessed using an AMS shift assay in the presence of increasing ratios of
DHLA/LA. Controls of the reduced (10mM TCEP, left lane) and oxidized (untreated protein, right lane) forms of the protein are included. See
Supplementary Fig. 6 for further discussion. (h–j) Depletion of TXNDC11 impairs the degradation of model glycoprotein ERAD substrates. (h) Immunoblot
validation of efﬁcient shRNA-mediated depletion of TXNDC11 in KBM7 cells. (i) KBM7 cell lines stably expressing ﬂuorescently tagged CD3d (top panel),
TCRa (middle panel) and NHK (bottom panel) were transduced with shRNA expression vectors targeting TXNDC11, and protein levels of the ERAD
substrates measured by ﬂow cytometry. (j) Depletion of TXNDC11 impairs the degradation of a NHK mutant lacking any cysteine residues. KBM7 cell lines
were established stably expressing mCherry-tagged NHK (top panel), NHK(QQQ), which cannot be N-glycosylated (middle panel) or NHK(C/S), which
lacks cysteine residues (bottom panel). The three cell lines were transduced with shRNA expression vectors targeting TXNDC11, and stabilization of NHK
protein levels was measured by ﬂow cytometry. Depletion of TXNDC11 impairs the ERAD of the NHK(C/S) mutant to a similar extent to that of wild-type
NHK, but does not have a signiﬁcant effect on the degradation of the non-glycosylated NHK(QQQ) variant.
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in which all N-glycosylated asparagine residues are mutated to
glutamine36, and NHK(C/S), in which the single cysteine residue
in NHK (through which it forms aberrant disulphide-bonded
dimers37) is mutated to serine (Fig. 3j). Consistent with the
notion that TXNDC11 acts in the glycoprotein ERAD pathway,
shRNA-mediated knockdown of TXNDC11 did not have a
signiﬁcant effect on the stability of the non-glycosylated
NHK(QQQ) variant (Fig. 3j). However, TXNDC11 depletion
impaired the degradation of the NHK(C/S) mutant similarly to
wild-type NHK (Fig. 3j). This demonstration that TXNDC11 is
required for the efﬁcient ERAD of a substrate that lacks any
cysteine residues supports the idea that the relevant target of the
TXNDC11 reductase activity may not be the ERAD substrate, but
rather another component of the ERAD machinery itself.
TXNDC11 binds known members of the ERAD machinery. To
gain further insight into the cellular role of TXNDC11, we sought
to identify TXNDC11 binding partners. Immunoprecipitation of
endogenous TXNDC11 from wild-type cells followed by mass
spectrometry (MS) (Fig. 4a) identiﬁed six putative interacting
proteins that were absent from control samples: the mannosidases
EDEM2 and EDEM3, the oxidoreductases PDI (encoded by
the P4HB gene) and TXNDC5, and both subunits of the alpha-
glucosidase complex38 (encoded by GANAB and PRKCSH)
(Table 1, Supplementary Fig. 7 and Supplementary Data 3).
These results ﬁrmly implicate TXNDC11 in glycoprotein quality
control, at the intersection of those pathways that regulate protein
folding, export from the ER, and targeting for ERAD (Fig. 4b).
The overlap between this proteomic dataset and our data from
the genetic screens indicated that the interactions between
TXNDC11 and EDEM2 and PDI were likely to be critical for
its role in ERAD (Fig. 4c), and knockout of TXNDC11 resulted in
increased levels of EDEM2 and EDEM3 (Fig. 4d). Finally we
found that TXNDC11 transcript levels were upregulated in
response to ER stress (Supplementary Fig. 8a), which could
potentially be mediated through a canonical ATF6 binding site39
in the TXNDC11 promoter (Supplementary Fig. 8b). Taken
together, these data suggest a model whereby the redox activity of
TXNDC11, acting in concert with EDEM proteins and PDI, is
required for glycoprotein ERAD.
Discussion
The aim of this study was to compare the effectiveness of
genome-wide CRISPR/Cas9-mediated forward genetic screens
with the ‘gold standard’ gene-trap haploid genetic screens at
identifying genes required for ERAD. We ﬁnd that both screening
modalities represent highly effective approaches to identify the
genes involved in the cellular pathways. A similar conclusion was
recently reached independently by Wang et al.,40 who showed
that, with the exception of the diploid chromosome 8, gene-trap
and CRISPR-mediated mutagenesis produced highly concordant
results in deﬁning the essential genes of KBM7 cells.
Our data demonstrate that FACS-based forward genetic
screens using ﬂuorescently tagged substrates represent an
effective approach to study the genes required for ERAD. The
genes identiﬁed by the haploid and CRISPR screens agree well
with our previous work using siRNA screening and candidate
gene approaches to deﬁne the genes involved in MHC-I ERAD.
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Figure 4 | TXNDC11 interacts with EDEM2/3 and the alpha-glucosidase complex. (a) Overview of the experiment designed to identify
TXNDC11-interacting partners by MS. (b) Schematic representation of the role of TXNDC11 and its binding partners in the ERAD pathway. (c) Overlap
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However, even the combination of hits from the two genetic
screens is unable to reach saturation. Our previous work
demonstrated a requirement for the p97 ATPase, its cofactor
Ufd1 and the ER lectin XTP3-B in MHC-I ERAD24, but these
components were not identiﬁed in either screen, possibly because
their depletion delays cell growth, or in the case of p97
components is lethal. We previously identiﬁed Hrd1 as the E3
ubiquitin ligase and UBE2J1 as the E2 ubiquitin conjugase
involved, together with a role for SEL1L and EDEM1 (refs 23,24).
The data from the genetic screens described here validate a role
for these factors, identify a role for additional genes known to be
involved in glycoprotein ERAD, and implicate TXNDC11 as a
novel gene required for MHC-I ERAD. TXNDC11 joins a
growing list of PDI-family proteins known to be involved in ER
homoeostasis41. In particular, there are intriguing parallels
between TXNDC11 and ERdj5, another ER-resident protein
that contains thioredoxin-like domains with highly reducing
active sites33,37. ERdj5 was originally identiﬁed as an interacting
partner of EDEM1 (ref. 37), while here we show that TXNDC11
binds to both EDEM2 and EDEM3. ERdj5 is thought to accelerate
ERAD by reducing disulphide bonds in the ERAD substrate itself,
before retrotranslocation37. Our data suggest that the relevant
target of TXNDC11 activity may not be the ERAD substrate itself,
as the cysteine-less substrate NHK(C/S) was also sensitive to loss
of TXNDC11, but rather a component of the ERAD machinery
(Supplementary Fig. 8).
There are advantages and disadvantages associated with each
genetic screening approach. From a practical standpoint, retro-
viral gene-trap mutagenesis is more straightforward as it does not
require the prior construction and propagation of a large sgRNA
library. The analysis of the screen by next-generation sequencing
is considerably easier for a CRISPR screen, however, requiring
only a routine PCR reaction to amplify the sgRNA sequences; a
more involved inverse PCR6 or LAM-PCR7 reaction is required to
amplify the genomic DNA ﬂanking retroviral gene-trap
integration sites. Another potential advantage of a retroviral
mutagen is that it will target all accessible chromatin, and
therefore has the capacity to identify unannotated genes and
regulatory genetic elements. Although it was not investigated
further, our haploid screen identiﬁed the antisense RNA encoded
by PRR7-AS1 as a putative hit, which is an example of a locus not
included in the GeCKO v2 sgRNA library. The CRISPR/
Cas9-mediated mutagenesis appeared to be more efﬁcient in
our comparison, however, leading to a greater proportion of
GFPhigh cells after the initial FACS enrichment. However, as we
carried out the CRISPR screen in a haploid KBM7 clone, it is
unclear from these data how far this efﬁciency might drop in
diploid cells. The real beneﬁts of the CRISPR approach lie in its
general applicability to non-haploid cells, including diploid cell
lines and primary cells. The modular nature of the CRISPR
system also makes it potentially far more versatile than gene-trap
mutagenesis. For example, CRISPR has already been adapted to
produce activation of gene expression and perform genome-wide
overexpression screens42,43. Ultimately the choice of cell type and
mutagenesis method will depend on the particular design of the
experiment, with the two methods providing complementary
approaches to examine gene function.
Methods
Cell culture. KBM7 cells, obtained from Dr Brent Cochran44, and HEK 293ET
cells, a generous gift from Dr Felix Randow, were cultured in IMDM plus 10% fetal
calf serum (FCS) and penicillin/streptomycin. HeLa cells were obtained from
ECACC and were grown in RPMI 1640 plus 10% FCS and penicillin/streptomycin.
Antibodies. Primary antibodies used were as follows: rabbit a-TXNDC11
(Abcam, ab188329; 1:5,000), rabbit a-FLAG (Sigma-Aldrich, F7425; 1:10,000),
mouse M1 a-FLAG (Sigma-Aldrich, F3040; 1:10,000), rabbit a-EDEM2
(Sigma-Aldrich, E1728; 1:5,000), rabbit a-EDEM3 (Sigma-Aldrich, E0409; 1:5,000),
rabbit a-PDI (Cell Signaling, #2446; 1:5,000), rabbit a-GANAB (GeneTex,
GTX102237; 1:5,000), rabbit a-SEL1L (Santa Cruz Biotechnology, sc-48080;
1:2,000), mouse a-calnexin (AF8, a kind gift from M. Brenner, Harvard Medical
School; 1:10,000) and mouse a-b-actin (Sigma-Aldrich, A5316; 1:10,000).
Lentiviral expression vectors. For CRISPR/Cas9-mediated gene disruption,
oligonucleotides (Sigma-Aldrich) for top and bottom strands of the sgRNA were
annealed, and then cloned into the lentiviral sgRNA expression vector
pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (Addgene #50946, kindly deposited by
Dr Kosuke Yusa19). Lentiviral expression of shRNA constructs was achieved using
the pHR-SIREN vector, with hairpins cloned in as BamHI–EcoRI fragments.
All sequences are detailed in Supplementary Data 4. For the expression of
exogenous genes, the vectors pHRSIN-PSFFV-GFP-PPGK-Hygro and pHRSIN-
PSFFV-GFP-PPGK-Blasto were used, with the gene of interest inserted in place of
GFP. Coding sequence for TXNDC11 (corresponding to Uniprot isoform 2,
identiﬁer Q6PKC3-2) that was sgRNA- and shRNA-resistant was ordered as a
series of gBlocks (IDT) and assembled using the Gibson Assembly method (NEB).
TXNDC11 mutants were created by site-directed mutagenesis using standard
protocols. In all cases, lentivirus was produced by transfecting HEK 293ET cells
with the lentiviral vector plus the packaging plasmids pCMVDR8.91 and pMD.G
using TransIT-293 reagent (Mirus) as recommended by the manufacturer. The
viral supernatant was collected 48 h later, passed through a 0.45 mm ﬁlter and target
cells transduced by spin infection at 700 g for 60min.
Haploid genetic screen. The haploid genetic screen was carried out exactly as
described11. Approximately 108 GFP-HLA-A2 KBM7 cells were mutagenized with
the gene-trap retrovirus Z-loxP-mCherry. The mutagenized cells were then grown
for 7 days before the ﬁrst sort to enrich for rare GFPhigh cells; a second sort was
performed to further purify the GFPhigh population 10 days later. Genomic DNA
was extracted (Puregene Core Kit A, Qiagen) from the resulting selected cells and
an aliquot of the unsorted mutagenized library grown for the same amount of time.
The retroviral gene-trap integration sites in both the control and selected
populations were then mapped by LAM-PCR as described previously11. For the
bubble plot presented in Fig. 1d, the degree of enrichment of each gene in the
selected population compared to the unselected cells was calculated using a
Bonferroni-corrected one-sided Fisher’s exact test. All genes found to contain
gene-trap integrations are listed alphabetically on the x axis; bubble size is
proportional to the number of unique gene-trap integrations predicted to inactivate
gene expression (given in parentheses).
CRISPR screen. The Cas9 nuclease was stably expressed in GFP-HLA-A2 KBM7
cells by lentiviral transduction. Approximately 108 cells were then transduced with
the GeCKO v2 sgRNA library (Addgene cat#1000000047, kindly deposited by
Prof. Feng Zhang30) at a multiplicity of infection of around 0.2. Untransduced
Table 1 | Identiﬁcation of TXNDC11 binding partners by mass spectrometry.
Wild-type TXNDC11 knockout
Peptides Coverage (%) Peptides Coverage (%)
Protein disulphide-isomerase (PDI) 22 40 1 3.1
ER degradation-enhancing alpha-mannosidase-like protein 2 (EDEM2) 20 37 0 0
Glucosidase 2 subunit alpha (GANAB) 19 23 0 0
Thioredoxin domain-containing protein 11 (TXNDC11) 19 22 0 0
ER degradation-enhancing alpha-mannosidase-like protein 3 (EDEM3) 15 21 0 0
Glucosidase 2 subunit beta (GLU2B) 13 26 0 0
Thioredoxin domain-containing protein 5 (TXNDC5) 10 28 0 0
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cells were removed from the library through puromycin selection (0.75 mgml 1)
commencing 48 h after transduction. Rare GFPhigh cells were then enriched by
sequential rounds of FACS, with the ﬁrst sort taking place 7 days after transduction
with the sgRNA library and the second sort a further 10 days later. Genomic DNA
was extracted (Puregene Core Kit A, Qiagen) from both the sorted cells and an
unselected pool of mutagenized cells grown for the same amount of time. sgRNA
sequences were ampliﬁed by two rounds of PCR, with the second round primers
containing the necessary adaptors for Illumina sequencing (Supplementary Data
4). Sequencing was carried out using a 50 bp single-end read on an Illumina
HiSeq2500 instrument using a custom primer binding immediately upstream
of the 20 bp variable segment of the sgRNA. The 30 end of the resulting reads
were trimmed of the constant portion of the sgRNA, and then mapped to an index
of all of the sgRNA sequences in the GeCKO v2 library using Bowtie 2. The
resulting sgRNA count tables were then analyzed using the RSA31, MAGeCK45
and HiTSelect46 algorithms using the default settings. For the bubble plot
presented in Fig. 2c, bubble size is proportional to the number of active sgRNAs
per gene.
Flow cytometry. Cells were washed once with PBS, ﬁxed in 1% PFA and analyzed
on a FACSCalibur (BD). For sorting, cells were resuspended in PBSþ 2% FCS and
FACS was carried on an Inﬂux cell sorter (BD).
Immunoﬂuorescence. HeLa cells were seeded on glass coverslips, ﬁxed with 4%
PFA, permeabilized with 0.5% Triton X-100, and then blocked for at least 30min
using 4% BSA dissolved in PBSþ 0.1% Tween-20 (PBS-T). Primary antibody
(diluted in blocking solution) was then applied for 1 h, and following ﬁve washes in
PBS-T, ﬂuorophore-conjugated secondary antibody was applied for 45min.
Coverslips were mounted in Prolong anti-fade reagent with DAPI (Molecular
Probes) and imaged using a Nikon LSM710 laser scanning confocal microscope
(Zeiss). Images were processed using Adobe Photoshop (Adobe, CA) or GIMP 2.
Plasmids for E. coli expression. Coding sequence to express the Trx5 domain of
TXNDC11, codon-optimized for E. coli, was ordered as a gBlock (IDT) and cloned
into the bacterial expression vector pET39b-Ub19 (a kind gift from Prof. V.
Do¨tsch, Goethe University Frankfurt, Germany47) between the NcoI and BamHI
restriction sites. To prevent the formation of disulphide-linked oligomers, a
non-active site cysteine residue was mutated to serine (C743S). The resulting
plasmid pLE524 encodes Ub-His-Trx5 C743S, containing N-terminal ubiquitin
and His tags, a TEV protease cleavage site, a four residue linker (GAMG) followed
by 123 residues of TXNDC11, encompassing the region from His650 to Asp772
(HLIGSyLHHSD). Two TXNDC11 Trx5-coiled-coil (CC) constructs were
created, one in the pET39b-Ub19 vector as described above (Ub-His-Trx5-CC
C743S/C788S encoded by pLE525) and the other in pMAL-c5x (NEB)
(MBP-Trx5-CC C743S/C788S encoded by pLE523), cloned in between the NdeI
and EcoRI sites (for an N-terminal maltose-binding protein tag). These constructs
encompassed the region of TXNDC11 from His650 to the end of the protein,
and contained two cysteine to serine mutations to prevent the formation of
disulphide-linked oligomers (C743S and C788S).
Expression and puriﬁcation of TXNDC11 constructs containing the coiled-coil
domain. Plasmids pLE523 and/or pLE525 were transformed into competent
BL21(DE3) cells and plated onto LB plates containing the appropriate antibiotic(s)
(ampicillin (100 mgml 1) and/or kanamycin (50 mgm 1l)). The plates were
grown overnight at 37 C. One colony was inoculated, and grown overnight in
125ml LB medium with appropriate antibiotic(s) at 37 C. The overnight culture
was diluted to an optical density at 600 nm (OD600) of 0.1 in LB medium con-
taining antibiotic(s) and grown at 37 C. At OD600¼ 0.75 protein expression was
induced with 1mM isopropyl b-D-1-thiogalactopyranoside (IPTG), and the cells
grown overnight at 20 C. Cells were harvested by centrifugation, and cell pellets
dissolved in 10ml fusion protein lysis buffer (50mM Tris, 25mM NaCl, 5% gly-
cerol, pH 7.8) with 1mM phenylmethylsulfonyl ﬂuoride (PMSF) and protease
inhibitor cocktail mixture (Roche) per litre of starting culture. Lysozyme (Merck)
was added to a ﬁnal concentration of 1mgml 1 and the cell suspension was
incubated for 1 h on ice. Finally, cells were broken open by sonication and then
centrifuged for 1 h at 27,000 g to generate the cleared lysate.
For Ni-NTA puriﬁcation, the cleared lysate containing co-expressed MBP-
Trx5-CC C743S/C788S and Ub-His-Trx5-CC C743S/C788S was ﬁltered and
diluted with an equal volume of Ni-NTA wash buffer (50mM Tris, 20mM
imidazole, 250mM NaCl, 1% glycerol, pH 7.8). This solution was then incubated
on a rolling table for 1 h and 15min at 4 C with Ni-NTA beads (Qiagen)
prewashed in Ni-NTA wash buffer. The beads were poured into an empty column
and the ﬂowthrough (FT) collected. Beads were then washed with 3 10 column
volumes (CVs) of Ni-NTA wash buffer followed by elution of bound proteins with
9 CVs of Ni-NTA elution buffer (50mM Tris, 400mM imidazole, 250mM NaCl,
1% glycerol pH 7.8). Selected fractions were separated on a 12% SDS–PAGE gel in
reducing loading buffer unless otherwise stated.
For amylose resin puriﬁcation, the FT from the Ni-NTA puriﬁcation was
diluted 10 times in amylose column buffer (20mM Tris–HCl, 200mM NaCl, pH
7.4) and incubated on a rolling table for 1 h and 15min at 4 C with amylose resin
(New England Biolabs) prewashed in amylose column buffer. The resin was poured
into an empty column and the FT collected. The resin was then washed with 5 4
CVs of amylose column buffer. Elution from the amylose resin was performed with
4 CVs of amylose elution buffer (20mM Tris–HCl, 200mM NaCl, 10mM maltose,
pH 7.4). Selected fractions were run on a 12% SDS–PAGE gel. The same protocol
was followed for the puriﬁcation of lysate containing only Ub-His-Trx5-CC C743S/
C788S with amylose resin.
Expression and puriﬁcation of the TXNDC11 Trx5 domain. Competent
BL21(DE3) cells were transformed with the plasmid pLE524 and plated on a LB agar
plate containing kanamycin (50mgml 1). The next day, one colony was inoculated
into 125ml LB medium with kanamycin and the culture grown
overnight at 37 C. The overnight culture was diluted in LB with kanamycin to an
optical density at 600nm (OD600) of 0.1 and grown at 37 C until the OD600 reached
0.75. Protein expression was induced by addition of 0.05mM IPTG and the cells were
cultivated at 20 C overnight. Cells were harvested by centrifugation and cell pellets
stored at  20 C until lysis. Cell pellets were dissolved on ice in 20ml lysis buffer
(50mM Na-phosphate, 300mM NaCl, 10mM imidazole, pH 8 containing protease
inhibitor cocktail and 1mM PMSF) per liter of starting culture. Cells were broken open
upon incubation with 1mgml 1 lysozyme on ice for 1h followed by sonication. The
lysate was centrifuged for 1h at 27,000 g at 4 C. The fusion protein was puriﬁed by
incubation of the ﬁltered supernatant with Ni-NTA beads (Qiagen) prewashed in Ni-
NTA binding buffer (50mMNa-Phosphate, 300mMNaCl, 10mM Imidazole, pH 8.0)
for 1 h and 15min at 4 C on a rolling table. The beads and supernatant were then
transferred to an empty column placed at 4 C and the FT collected. The beads were
washed with at least 25 column volumes (CVs) of Ni-NTA wash buffer (50mM Na-
phosphate, 300mM NaCl, 20mM Imidazole, pH 8.0) and 10ml wash fractions were
collected. Elution of bound Ub-His-Trx5 C743S was achieved by addition of 15 CVs of
Ni-NTA elution buffer (50mM Na-phosphate, 300mM NaCl, 400mM Imidazole, pH
8.0), and the protein visualized on a Coomassie-stained 15% reducing SDS–PAGE gel.
Relevant fractions were pooled before cleavage of the Ub-His-tag, which was done by
incubation of the protein pool with 1mM EDTA, 10mM b-mercaptoethanol and the
sTEV protease (plasmid was a kind gift from Prof. V. Do¨tsch, Goethe University
Frankfurt, Germany) in a ratio of 1:25 sTEV:Ub-His-Trx5 C743S at room temperature
for 3 h. Next, the cleavage reaction solution was dialyzed into Ni-NTA binding buffer
at 4 C overnight. To bind the cleaved Ub-His-tag, the dialyzed protein pool was
incubated with Ni-NTA beads as described above. In most cases, small amounts of Ub-
His-tag were still present in the FT. In these cases, the FT was re-incubated with Ni-
NTA beads to bind the remaining Ub-His-tag. Next, the FT was concentrated to
A280¼ 0.5 using an Amicon spin ﬁlter. To remove the remaining contaminants, the
concentrated protein pool was centrifuged for 15min at 16,100 g at 4 C and loaded
on a Superdex75 (GE Healthcare) gel ﬁltration column. The Trx5 C743S domain was
eluted isocratically in Trx5 C743S storage buffer (50mM Na-phosphate, 150mM
NaCl, pH 7.0). The eluted fractions were analyzed by SDS–PAGE and pooled based on
purity. The concentration of Trx5 C743S was calculated from the absorbance at
280nm (recorded on a Zeiss Specord S10 with Aspect Plus software) and a theoretical
extinction coefﬁcient for oxidized Trx5 C743S of 21095M 1cm 1 (ref. 48). Matrix
assisted laser desorption ionization time-of-ﬂight MS (MALDI-TOF MS) was
performed on a Bruker Autoﬂex mass spectrometer. Sample preparation was carried
out according to the dried droplet method using a-cyano-4-hydroxycinnamic acid
(HCCA) matrix. Trx5 C743S was diluted to 3.75mM in 0.2% TFA and mixed 1:1 with
HCCA matrix solution (HCCA in 1:2 Acetonitrile:0.1% TFA). The spectrometer was
calibrated using a quadratic ﬁt to a set of standard proteins (Protein calibration
standard 14,000–20,000Da (Bruker)).
CD spectroscopy. Puriﬁed Trx5 C743S was concentrated to A280¼ 0.5 (23 mM)
and dialyzed into CD buffer (10mM Na-phosphate, pH 7.0) overnight at 4 C.
Before the CD measurements, the dialyzed protein was centrifuged for 30min at
4 C at 16,100 g. The spectrum of the reduced form of Trx5 C743S was recorded
on a sample pre-incubated for 1 h at 4 C and 2.5 h at room temperature. The
spectra were recorded at 5 C at a scan rate of 20 nmmin 1 from 260 to 190 nm on
a Jasco-J810 spectropolarimeter equipped with a Peltier temperature control device.
The spectra were recorded as an accumulation of 15 scans. Upon recording, all data
sets were subtracted the buffer baseline and noise-reduced with a fast Fourier
transform ﬁlter in the Spectra Manager software. The resulting ellipticities were
normalized to concentration and number of amino acids using the equation:
y½ MRW¼
y MW
10  C  l  N
where y is the ellipticity in degrees, MW is the molecular weight in gmol 1, C is
the concentration of oxidized Trx5 C743S in gml 1, l is the path length in cm and
N is the number of amino acids in the sequence. For protein concentration
determination, the absorbance at 280 nm was recorded immediately after the CD
measurement of each sample on a UV-Vis spectrophotometer. The redox state of
the proteins were quenched with 20% TCA and analyzed using the AMS shift assay
(see below).
AMS modiﬁcation. In a ﬁnal volume of 100ml, 0.4 nmol puriﬁed Trx5 C743S was
incubated with various reducing agents. Upon incubation, the redox state of the
reactants was quenched with 20% TCA and protein precipitated for at least 30min
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on ice. The precipitate was pelleted by centrifugation for 15min at 4 C at
16,100 g and the supernatant discarded. Upon another centrifugation for 1min,
the remaining supernatant was discarded and 10 ml AMS buffer (0.4M Tris–HCl
pH 7.5, 1.6% SDS, 0.1 % bromocresolpurple, 15mM AMS (4-acetamido-40-mal-
eimidylstilbene-2,20-disulfonic acid; Fluka)) was added. The pH of the solution was
titrated with 1.5M Tris–HCl pH 8.8 until a colour shift was observed (usually 1 ml
was enough). The pellets were dissolved by vortexing for 1min and the AMS
modiﬁcation reaction carried out for 2 h at room temperature in the dark. Samples
were then boiled in non-reducing loading buffer for 5min, spun down and stored
at  20 C before analysis on 18% SDS–PAGE gels.
Redox titration using lipoic acid. Stock solutions of 30mgml 1 dihydrolipoic
acid (DHLA) (Sigma) and 50mgml 1 lipoic acid (LA) (Sigma) were prepared in
96% nitrogen-ﬂushed ethanol and kept at  20 C. Before setting up the
experiment, the actual concentration of the DHLA stock was calculated using
Lambert Beers law from the absorbance of Ellman’s reagent (1mM 5,50-dithiobis-
(2-nitrobenzoic acid), 50mM K-phosphate, 0.1mM EDTA, pH 7.3) at 412 nm and
the extinction coefﬁcient 14,150M 1 cm 1 (ref. 49). The amount of oxidized LA
in the DHLA stock was determined from the absorbance at 333 nm and the
extinction coefﬁcient for oxidized LA in ethanol 170M 1 cm 1 (ref. 50). The
actual concentration of the LA stock was determined similarly. Since the solubility
of DHLA/LA is quite low in aqueous solution, the stock solutions were diluted in
nitrogen-ﬂushed 96% ethanol in appropriate concentrations, so when added to the
redox titration samples, a ﬁnal concentration of 11.5% ethanol was reached.
In the redox titration experiment, Trx5 C743S (4 mM) in nitrogen-ﬂushed
50mM Na-phosphate, 150mM NaCl, 1mM EDTA, pH 7.0 was incubated with
theoretical DHLA/LA ratios ranging from 10 to 0.01 in a total volume of 100 ml. As
air-oxidation of DHLA during the experiment would affect the resulting reduction
potentials of the buffers, a set of blank samples identical to each protein sample
(except that no protein was added) was prepared. After 16 h of incubation at 25 C
with shaking, the redox state of the protein samples was quenched by the addition
of 20% TCA. The protein was precipitated on ice for at least 30min, and the AMS
modiﬁcation protocol described above was followed. The blank samples were put
on ice, and the actual DHLA and LA concentrations in each blank sample were
determined spectrophotometrically using the methods described above. The only
exception was that LA was measured at 330 nm using the extinction coefﬁcient
127M 1 cm 1 for LA in phosphate buffer51. The reduction potential of the blank
samples was calculated from the determined DHLA/LA ratios using the Nernst
equation. A standard reduction potential of DHLA/LA of  290mV was used52.
Immunoblotting. Cells were lysed in 1% digitonin in TBS plus 10mM
iodoacetamide (IAA), 0.5mM PMSF on ice for 30min. Following centrifugation at
13,000 g for 10min, the post-nuclear supernatant was heated to 70 C in SDS
sample buffer for 10min, separated by SDS–PAGE, and transferred to a PVDF
membrane (Millipore). Membranes were blocked in 5% milk in PBSþ 0.2%
Tween-20, probed with the indicated antibodies, and reactive bands visualized
using West Pico or West Dura (Thermo Fisher Scientiﬁc). Uncropped gel images
can be found in Supplementary Fig. 9.
Co-immunoprecipitation and MS. For immunoprecipitation, digitonin lysates
were pre-cleared with protein A and IgG-sepharose and incubated with primary
antibody and protein A- or protein G-sepharose for 2 h at 4 C. Following three
washes in lysis buffer, samples were eluted in SDS sample buffer. For analysis by MS,
immunoprecipitates were ﬁrst resolved by SDS–PAGE, with each lane being cut into
four slices for in-gel digestion. Tryptic peptides were analyzed by LC–MS/MS and
the raw ﬁles processed in Proteome Discoverer 1.4. Data was searched using Sequest
against the Human Uniprot database (downloaded 03/03/14, 68710 sequences).
qRT-PCR. The RNeasy Plus kit (Qiagen) was used to extract RNA, which was then
reverse transcribed using a poly(d)T primer and Super RT reverse transcriptase
(HT Biotechnology). All reactions were performed using 4 ng of cDNA, 10 ml of
SYBR green PCR mastermix (Life Technologies) and 0.2 mM forward and reverse
primers in a ﬁnal reaction volume of 25 ml. Samples were run on an ABI 7,500 Real
Time PCR System (Applied Biosystems), with cycling parameters of 50 C for
2min and 95 C for 5min, followed by 40 cycles of 95 C for 15 s and 58 C for
1min. Primer sequences can be found in Supplementary Data 4.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
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